A Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study to Assess Safety and Tolerability of TTP435 in Obese (Class 1-2) Subjects Over 8 Weeks of Treatment.
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2015
At a glance
- Drugs TTP 435 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors TransTech Pharma; vTv Therapeutics
- 21 Jul 2010 Actual patient number is 100 as reported by ClinicalTrials.gov.
- 21 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 21 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.